Aileron Therapeutics analyst ratings
Aileron Therapeutics analyst ratings
While ratings are subjective and will change, the latest Aileron Therapeutics (ALRN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Aileron Therapeutics (ALRN) is trading at is $0.28, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/29/2022 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 06/05/2020 | 620.46% | HC Wainwright & Co. | $3 → $2 | Maintains | Buy |
| 03/31/2020 | 980.69% | HC Wainwright & Co. | $6 → $3 | Maintains | Buy |
| 04/09/2019 | 1701.15% | Canaccord Genuity | $19 → $5 | Maintains | Buy |
| 03/11/2019 | 2421.61% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 07/24/2017 | 7104.61% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 07/24/2017 | 6744.38% | B of A Securities | → $19 | Initiates Coverage On | → Buy |
| 07/24/2017 | 6744.38% | Canaccord Genuity | → $19 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 06/29/2022 | — | 威廉布萊爾 | 降級 | 跑贏大盤 → 市場表現 | |
| 2020 年 5 月 6 日 | 620.46% | HC Wainwright & Co. | 3 美元 → 2 美元 | 維持 | 購買 |
| 2020 年 3 月 31 日 | 980.69% | HC Wainwright & Co. | 6 美元 → 3 美元 | 維持 | 購買 |
| 2019 年 9 月 4 日 | 1701.15% | Canaccord Genu | 19 美元 → 5 美元 | 維持 | 購買 |
| 2019 年 11 月 3 日 | 2421.61% | HC Wainwright & Co. | → 7 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/24/2017 | 7104.61% | 傑富瑞集團 | → 20 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/24/2017 | 6744.38% | B of A 證券 | → 19 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/24/2017 | 6744.38% | Canaccord Genu | → 19 美元 | 啓動覆蓋範圍開啓 | → 購買 |
Aileron Therapeutics Questions & Answers
Aileron Therapeutics 問題與解答
The latest price target for Aileron Therapeutics (NASDAQ: ALRN) was reported by William Blair on June 29, 2022. The analyst firm set a price target for $0.00 expecting ALRN to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
威廉·布萊爾於2022年6月29日公佈了Aileron Therapeutics（納斯達克股票代碼：ALRN）的最新目標股價。該分析公司將目標股價設定爲0.00美元，預計ALRN將在12個月內跌至0.00美元（可能下跌-100.00％）。去年有1家分析公司公佈了評級。
The latest analyst rating for Aileron Therapeutics (NASDAQ: ALRN) was provided by William Blair, and Aileron Therapeutics downgraded their market perform rating.
Aileron Therapeutics（納斯達克股票代碼：ALRN）的最新分析師評級由威廉·布萊爾提供，Aileron Therapeutics下調了其市場表現評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aileron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aileron Therapeutics was filed on June 29, 2022 so you should expect the next rating to be made available sometime around June 29, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Aileron Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Aileron Therapeutics的最後一次評級是在2022年6月29日發佈的，因此您應該預計下一個評級將在2023年6月29日左右公佈。
While ratings are subjective and will change, the latest Aileron Therapeutics (ALRN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Aileron Therapeutics (ALRN) is trading at is $0.28, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但Aileron Therapeutics（ALRN）的最新評級下調，目標股價爲0.00美元至0.00美元。Aileron Therapeutics（ALRN）目前的交易價格爲0.28美元，超出了分析師的預期區間。
